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ABSTRACT  
 
Piroxicam is antiinflammatory non-steroidal (AINS) drug group that has anti-inflammatory, 
analgesic and antipyretic effects. Like most other AINS drugs, piroxicam has low solubility and has 
gastrointestinal (ulcerogenic) side effects on long-term use. The nano-emulsifying drug delivery 
system (SNEDDS) is one of the technologies that can be used to overcome it. This study aims to 
determine the effect of ulcerogenic SNEDDS piroxicam compared with piroxicam formulas instead 
of SNEDDS. This study used white rats male strain Sprague Dawley (SD) age 2-3 months and 
weight 100-200 g of 40 rats. Rats divided into 5 groups. Group I was a normal control group, 
which were given only water. Group II was a vehicle control group which treated with a 1% 
polyvinylpyrrolidone (PVP) solution, group III was a carrier control group which treated with 
SNEDDS base (a mixture of tween 80, virgin coconut oil (VCO) and polyethylene glycol (PEG) 
400), group IV was a group of piroxicam which reated with  piroxicam 1.08 mg/Kg suspended 1% 
PVP, group V was treated with SNEDDS piroxicam. Treatment was done for 28 days. After 
treatment, the gastric of rats were taken to be observed for ulcerogenic effects. Observations were 
made macroscopically by looking at ulcer scores followed by histopathological observations of 
tissue. The ulcer score data from each group were analyzed using one-way ANOVA and LSD test. 
The results showed that the normal control group, 1% PVP suspension and SNEDDS base  groups 
had an ulcer index of 0.0, 0.0 and 0.0 respectively, while the piroxicam suspension and the 
SNEDDS groups had an ulcer index of 0.88 and 0.0. These results were confirmed by 
histopathologic results of SNEDDS piroxicam in order to decrease the effect of piroxicam 
ulcerogenic. It can be concluded that SNEDDS piroxicam can decrease the ulcerogenic effect.  
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INTRODUCTION  
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to reduce 
pain and swelling (Wallace and Vong, 2008). NSAID drugs have side effects of gastrointestinal 
disorders. Symptoms of gastrointestinal disorders such as dyspepsia occur in 15-60% of users of 
OAINS and peptic ulcers ranging from 0.1-0.19% of the total patients (Sung et al., 2009). Hospital-
based endoscopic data showed gastrointestinal complications resulting from the use of NSAID in 
Makassar 71%, Jakarta 67.7%, and Surabaya 61% (Margaretha et al., 2011). WHO data showed 
that the deaths caused by peptic ulcers in Indonesia reached 0.99%, which is obtained from the 
death rate of 8.41 per 100,000 population. Peptic ulcer was ranked 10th in the category of causes of 
death in the age group of 45-54 years in men according to BPPK Depkes. 
Piroxicam like other OAINS can cause side effects on the digestive tract, one of which is a 
peptic ulcer. It has been reported that OAINS crystals have poor solubility in gastric acid and 
contact with the gastric wall for prolonged periods resulting in dangerous local concentrations. This 
causes local irritation of the stomach wall followed by ulceration (Nagarsenker et al., 2000). In 
addition, the systemic piroxicam inhibits COX so that prostaglandin synthesis is hampered (Laine 
et al., 2008). The hamperation of mucosal prostaglandin synthesis will lead to peptic ulcers (Kumar 
et al., 2007). 
Piroxicam is a second class drug in Biopharmaceutical Drug Classification System (BCS) 
which have a low dissolution and high permeability (Blagden et al., 2007). The absorption rate and 
bioavailability rate for the hydrophobic drug are controlled by the dissolution rate in the digestive 
fluid. From the previous research we have obtained the optimum formula of self-nano emulsifying 
drug delivery system (SNEDDS) piroxicam (Dewi, 2016). SNEDDS is a mixture of isotropic oil 
phases, surfactants, cosurfactants and drugs that make up nanoemulsion of oil in water when added 
to the aqueous phase under slow stirring (Wang et al., 2009). The nanoemulsion protects the drug 
particles that can not dissolve in the stomach fluid, so that the particles are not in direct contact 
with the gastric mucosa (Anuradha et al., 2013). This research aimed to investigate the decrease of 
ulcerogenic effects of SNEDDS piroxicam with VCO as oil phase, tween 80 as surfactant and PEG 
400 as cosurfactant compared with piroxicam formulas instead of SNEDDS. 
  
MATERIALS AND METHOD  
Materials 
Piroxicam (pharmaceuticals) grade which used for study was found from PT Indofarma Tbk. 
 
Production of SNEDDS Piroxicam 
SNEDDS piroxicam was made with a composition of 12% VCO; 64% tween 80; 24% 
PEG 400 v/v and 10 mg/mL piroxicam (Dewi, 2016). VCO, tween 80 and PEG 400 were 
mixed in vials, then vortexed (mix) for 5 minutes. Followed by sonication for 5 minutes and 
heated for 5 minutes with a temperature of 45 oC. The next step of piroxicam is mixed in the 
mixture. The piroxicam in the carrier was then homogenized with a vortex for 5 minutes, with 
a sonicator for 5 minutes, heated in a 45 °C waterbath for 5 minutes. Repeat the cycle 
procedure 2 times. 
 
Characteristics Test of SNEDDS piroxicam 
Clarity test 
Clarity test was done through transmittance reading with spectrophotometer. One 
hundred microliter the piroxicam SNEDDS formula was taken and then added up to 5 mL of 
aquadest, then vortex for 1 min to mix it into homogenus. Furthermore, transmittance percent 
reading was done at 650 nm wavelength with aquadest blanks (Lalwani et al., 2013). The 
reading was  conducted 3 times. 
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Emulsification time test 
The emulsification time test wasperformed using type 2 dissolution apparatus with 
aquadest as its medium. A total of 500 mL of aquadest was conditioned on the device with a 
temperature of 37oC. One mililiter SNEDDS piroxicam was included in the medium along 
with rotating the paddle at 100 rpm. The obtained time is calculated starting from SNEDDS 
entering to form a clear solution in aquadest medium. The time obtained is then recorded and 
replicated 3 times (Balakumar et al., 2013). 
 
Ulcerogenic  test 
All test protocols have been approved by the Universitas Ahmad Dahlan Ethics 
Committee with Ref number 011702020. The test animal used  was white male rats of SD aged 
2-3 months with body weight 150-200 g obtained from animal trader test from Solo. The rats 
were divided into 5 groups with 8 rats of each,i.e : 
a. Group I: given by water, as a normal control. 
b. Group II was given by  a 1% PVP solution, as a vehicle control. 
c. Group III was given a mixture of tween 80, VCO, PEG 400, as a SNEDDS base 
control. 
d. Group IV was given a suspected piroxicam dose of 1.08 mg/Kg in 1% PVP. 
e. Group V was given SNEDDS piroxicam dose of 1.08 mg/Kg BW.  
Treatment was done orally once daily for 28 days. On the 29th day the rats were 
sacrificed by anesthetized with either then performed surgery. The stomach was removed, then 
the gastric mucosa was opened along the major curvatura, washed with physiological NaCl. 
After that, spread on a flat surface and then photographed, macroscopically observed, then 
scored according to (Szabo et al., 1985) modified. 
Microscopic observation was performed by observing histopathology of gastricmucosa  
The gastrics were cleaned with physiological NaCl, then stored in pots containing 10% 
technical formalin. Preparationwas carried outby standard method in Pathology Laboratory, 
Faculty of Veterinary Medicine of UGM. Observation of histopathologic preparations were 
performed using the Optilab apparatus.  
 
Data Analysis 
The number of ulcers were counted and the ulcer index calculated using the method 
described by Szabo et al., (1985) with equation 1. 
 
The ulcer index = Mean (hyperemia score + hemorrhage score  + erosion score) ……(1)   
 
RESULT AND DISCUSSION  
Characteristics of SNEDDS Piroxicam 
    The resulting SNEDDS piroxicam characters has met the clarity and emulsification time. 
Clarity is expressed in percent transmittance. Measurement of transmittance percent was done to 
prove that the emulsion droplet which has reached the nanometer size (less than 100 nm). The 
results show that the average transmittance value of three replications are 99.38% ± 0.23. Because 
this value is close to 100%, so it can be stated that the emulsion droplet in SNEDDS piroxicam 
formula has reached nanometer size (Bali et al., 2010). The size of the dispersed phase greatly 
affects the appearance of the emulsion. When the nanoemulsion formed is passed through the light, 
the light beam is transmitted, resulting in a large transmittance value (Sahumena, 2014). 
        The emulsification time is the time which was taken to form a homogeneous mixture in a 
medium with light stirring. This character describes the time SNEDDS take to form an emulsion in 
the gastrointestinal tract. SNEDDS should be able to form spontaneous nanometer-sized emulsions 
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in the gastrointestinal tract with mild agitation such as peristaltic. SNEDDS should be good enough 
when the emulsification time is produced in less than a minute with a clear and transparent 
appearance (Balakumar  et al., 2013). The results showed that the emulsification time of SNEDDS 
piroxicam was able to fully emulsified to form nanoemulsion in less than one minute ie 38.97 
seconds ± 7.14. When the emulsion is formed there is interaction between tween 80 and PEG 400. 
PEG 400 as cosurfactant can increase fluidity through penetration and form empty space between 
surfactant molecules, so PEG 400 plays a role in accelerating emulsification time (Belhadj et al., 
2013). 
 
The ulcerogenic effect of SNEDDS piroxicam on macroscopic observation 
The gastric macroscopic differences on each treatment is exhibited in Figure 1. The 
macroscopic observation of the gastric mucosa  shows that of the giving of piroxicam with a dose 
of 1.08 mg/Kg (group IV) for 28 days may lead to a peptic ulcer in  rats. These results are 
consistent with the study (Nagarsenker et al., 2000) who reported that OAINS crystals have poor 
solubility in gastric acid and contact with the gastric wall for prolonged periods to produce 
concentrations causing local irritation of the stomach wall followed by ulceration (Nagarsenker et 
al., 2000). Otherwise, the systemic piroxicam inhibits COX so that prostaglandin synthesis is 
inhibited. Inhibition of prostaglandin synthesis will decrease mucosal resistance and trigger gastric 
mucosal damage (Laine et al., 2008). 
      There was no hemorrhage found in the SNEDDS piroxicam treated groups as well as the 
group given SNEDDS carrier which was a mixture of 12% VCO; 64% tween 80; 24% PEG 400 
v/v. This result shows that the formulation of SNEDDS piroxicam can protect the hemorrhagic 
occurrence of rat stomach. 
         Observation of gastric ulcer severity index was performed according to (Szabo et al., 1985) 
modified. The results of the SNEDDS ulcer index can be seen in Table I. The results of the ulcer 
index are used to assess the state of the peptic ulcer formed. According to Table I, it was seen that 
in the groups given the piroxicam susupension had a severity index of 0.88 greater than the 
piroxicam SNEDDS group and the control group. The results of this ulcer indicated that the 
SNEDDS piroxicam formulation can protect the occurrence of ulcers compared to the piroxicam 
suspension group.Result and discussion should be combined in the manuscript. It is should be 
described concisely. Text, tables and figures must be internally consistent. Discussion should 
involve the significant findings presented with relevant and extensive discussion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Macroscopic of stomach: A. Piroxicam suspension occurs hemorage  B. SNEDDS base  
control does not change, C. Suspension control does not change, D. Piroxicam SNEDDS does  
not change, E. Normal control does not change 
 
A.Piroxicam suspension  B. SNEDDS base  
E. Normal control 
C. Suspension control  
D. SNEDDS 
piroxicam  
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Table I. The mean of ulcer index (x ± SD) ) after treatment with  SNEDDS piroxicam 
  
Group (n=6) Ulcer Index 
 Normal control 0.00 ± 0.00 
Suspension control  0.00 ± 0.00 
SNEDDS base control 0.00 ± 0.00 
Piroxicam suspension 0.88 ± 0.08 
Piroxicam SNEDDS 0.00 ± 0.00 
 
Microscopic stomach organs 
 Microscopic observations of the gastric mucosa were performed to observe gastric 
conditions at a cellular level which not seen in macroscopic observations. The staining organ was 
performed by hematoxillyne and eosin (HE) dyes. The hematoxillyne dye is an alkaline dye that 
will give a blue or purple color to the acid component including the nucleus, while the eosin dye is 
an acid dye that gives the pink color in the cytoplasmic base component (Mescher, 2011). The 
histopathological results of the gastric mucosa is showed in Figure 2. 
The result of histopathological observations on normal control (water), 1% PVP suspending 
control and carrier controls appear to be unchanged or tissue seen to be normal. In the  piroxicam 
suspension group there is a change of erosion (Figure 1 A). In the piroxicam SNEDDS group there 
was no change. Mucosal damage can be said to erosion if the depth is less than 5 mm. If the 
mucosal damage reaches 5 mm or more until it reaches submucosa with necrosis it is called ulcer 
(Puspitasari, 2008). Cell damage (necrosis) will stimulate the release of inflammatory mediators. 
The task of this inflammatory mediator begins with acute inflammation and ends with healing 
(Reid et al., 2011). This histopathological observation showed that the ulcerogenic effect was seen 
only in the piroxicam suspension group (Figure 2D), so it can be concluded that SNEDDS 
piroxicam formulas are able to protect the stomach from the ulcerogenic effects of piroxicam. 
 Piroxicam is known to cause ulcerogenic effects in the stomach. Ulcerogenic caused by 
topical effects as well as systemic effects. Topical effects occur because the piroxicam is acidic and 
lipophilic. Piroxicam has a weak acidic nature, so in the gastric fluid piroxicam is in unionized 
form and dissolves in lipids. Piroxicam diffuses through the gastric epithelial cell membrane to the 
cytoplasm, where the pH is neutral. At that pH, piroxicam is converted to ionized and lipophobic 
forms, so that piroxicam is trapped in the cell and causes cellular damage (Matsui et al., 2011). In 
some studies and articles mentioned that piroxicam and other AINS drugs have low solubility in 
stomach acid and are in direct contact with the gastric wall for long periods of time, resulting in 
dangerous local concentrations. It causes local irritation of the stomach wall and ulcers (Anuradha 
et al., 2013). Systemic effect of piroxicam occurs by inhibition of cyclooxygenase enzyme (COX) 
in arachidonic acid so that prostaglandin and prostacyclin production is reduced. Prostaglandins are 
found in the gastric mucosa. Prostaglandins are a cytoprotective substance for the gastric mucosa 
performed by maintaining mucosal blood flow, increasing mucus secretion and bicarbonate ions, 
reducing gastric acid secretion and enhancing epithelial defenses (Wallace, 2008). Through 
inhibition of this prostaglandin causes protection of the gastric mucosa of the insoluble piroxicam 
particles decreases. 
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Figure 2. Microscopic profile of SNEDDS piroxicam: (A) Normal control, (B) Suspension control, (C) 
SNEDDS base control, (D) Piroxicam suspension group with erosi (   ), (E) Piroxicam 
SNEDDS group 
 
 The results of this study are in line with the study (Putri, 2012) on the reduction of the 
piroxicam ulcerogenic effect through the formation of piroxicam-PVP solid dispersions in male 
white rats. Similar results are also obtained (Obitte et al., 2013) on the decline in the ulcerogenic 
effects of piroxicam on solid lipid microparticle delivery. Nanoemulsion on SNEDDS protects drug 
particles that are insoluble in gastric fluid, so that the particles do not come into direct contact with 
the gastric mucosa (Anuradha et al., 2013). This protection is thought to decrease the ulcerogenic 
effect of piroxicam. 
 
CONCLUSION  
The results showed that SNEDDS piroxicam with VCO as oil phase, tween 80 as surfactant 
and PEG 400 as cosurfactant decreased the ulcer score compared with piroxicam suspension. 
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